

Timothy Beukelman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2137795/publications.pdf>

Version: 2024-02-01

114
papers

8,098
citations

61857

43
h-index

49773

87
g-index

134
all docs

134
docs citations

134
times ranked

6885
citing authors

#	ARTICLE	IF	CITATIONS
1	Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Rheumatology</i> , 2023, 62, 804-814.	0.9	2
2	Effectiveness and Safety of High-Dose Biologics in Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance. <i>Arthritis Care and Research</i> , 2022, 74, 1770-1779.	1.5	4
3	Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrhumdis-2021-221694.	0.5	7
4	Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1322-1329.	1.0	10
5	Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B*27, and Equal Sex Representation in Sacroiliitis. <i>Arthritis Care and Research</i> , 2021, 73, 940-946.	1.5	15
6	Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children. <i>American Journal of Epidemiology</i> , 2021, 190, 403-412.	1.6	7
7	Making Decisions About Stopping Medicines for Well-Controlled Juvenile Idiopathic Arthritis: A Mixed-Methods Study of Patients and Caregivers. <i>Arthritis Care and Research</i> , 2021, 73, 374-385.	1.5	17
8	Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Pediatric Rheumatology</i> , 2021, 19, 131.	0.9	3
9	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , 2021, 73, 1898-1909.	2.9	19
10	Pharmacovigilance in Juvenile Idiopathic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 643-653.	0.8	5
11	Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 326-334.	2.9	197
12	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1945-1951.	2.9	28
13	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 1040-1041.	2.9	0
14	Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. <i>Arthritis Care and Research</i> , 2019, 71, 482-491.	1.5	65
15	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1976-1984.	2.9	8
16	The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United States. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 77-78.	1.0	9
17	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. <i>Arthritis Care and Research</i> , 2019, 71, 703-716.	1.5	176
18	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Entesitis. <i>Arthritis Care and Research</i> , 2019, 71, 717-734.	1.5	225

#	ARTICLE	IF	CITATIONS
19	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 846-863.	2.9	110
20	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 864-877.	2.9	57
21	Primary Oral Presentation of Sarcoidosis in a Pediatric Patient. <i>Journal of Oral and Maxillofacial Surgery</i> , 2019, 77, 1180-1186.	0.5	1
22	Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review. <i>Pediatric Rheumatology</i> , 2019, 17, 77.	0.9	12
23	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , 2019, 71, 451-459.	2.9	36
24	Juvenile Idiopathic Arthritis: An Idea Whose Time Has Gone?. <i>Journal of Rheumatology</i> , 2019, 46, 124-126.	1.0	16
25	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1508-1518.	2.9	26
26	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1012-1016.	0.5	48
27	High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. <i>Arthritis and Rheumatology</i> , 2018, 70, 594-605.	2.9	11
28	Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). <i>Clinical Trials</i> , 2018, 15, 268-277.	0.7	19
29	Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. <i>Journal of Rheumatology</i> , 2018, 45, 107-114.	1.0	14
30	Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 189-190.	1.0	21
31	Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. <i>Pediatric Rheumatology</i> , 2018, 16, 71.	0.9	34
32	Risk Factors for Intraarticular Heterotopic Bone Formation in the Temporomandibular Joint in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1301-1307.	1.0	30
33	Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population. <i>JAMA Internal Medicine</i> , 2018, 178, 1224.	2.6	19
34	Juvenile Idiopathic Arthritis. <i>Pediatric Clinics of North America</i> , 2018, 65, 657-674.	0.9	43
35	Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. <i>Journal of Rheumatology</i> , 2017, 44, 352-360.	1.0	31
36	Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease Outcomes. <i>Arthritis Care and Research</i> , 2017, 69, 1617-1619.	1.5	1

#	ARTICLE	IF	CITATIONS
37	Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States. <i>Arthritis and Rheumatology</i> , 2017, 69, 1733-1740.	2.9	59
38	Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , 2017, 184, 38-44.e1.	0.9	48
39	Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. <i>Journal of Pediatrics</i> , 2017, 189, 31-39.	0.9	3
40	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1884-1888.	1.0	11
41	Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. <i>Pediatric Rheumatology</i> , 2017, 15, 23.	0.9	41
42	The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. <i>Pediatric Rheumatology</i> , 2017, 15, 30.	0.9	80
43	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. <i>Pediatric Rheumatology</i> , 2017, 15, 31.	0.9	27
44	Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2017, 15, 52.	0.9	19
45	Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. <i>Arthritis Research and Therapy</i> , 2017, 19, 84.	1.6	46
46	Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study. <i>Pediatric Rheumatology</i> , 2017, 15, 79.	0.9	8
47	The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 210.	1.6	34
48	Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1803-1811.	1.5	15
49	Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2016, 14, 49.	0.9	12
50	A Heterozygous <i>RAB27A</i> Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. <i>Journal of Immunology</i> , 2016, 196, 2492-2503.	0.4	77
51	Trial Design, Measurement, and Analysis of Clinical Investigations. , 2016, , 54-77.e2.		4
52	Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. <i>Arthritis and Rheumatology</i> , 2016, 68, 56-66.	2.9	136
53	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. <i>JAMA Dermatology</i> , 2016, 152, 164.	2.0	131
54	Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project. <i>Arthritis Care and Research</i> , 2015, 67, 529-537.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2015, 42, 541-546.	1.0	46
56	Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy. <i>Arthritis Care and Research</i> , 2015, 67, 731-736.	1.5	94
57	Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2155-2159.	1.0	14
58	Impact of Biologic Agents With and Without Concomitant Methotrexate and at Reduced Doses in Older Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 624-632.	1.5	41
59	Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1065-1071.	0.5	79
60	Changes in Body Mass Index in Children with Juvenile Idiopathic Arthritis Treated with Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2014, 41, 113-118.	1.0	6
61	Adding Canakinumab to the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Systemic Juvenile Idiopathic Arthritis: Comment on the Article by DeWitt et al. <i>Arthritis Care and Research</i> , 2014, 66, 1430-1431.	1.5	28
62	A20: Understanding the Use and Biology of TNF Therapy in JIA-Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2014, 66, S31-S32.	2.9	1
63	Development and Retrospective Validation of the Juvenile Spondyloarthritis Disease Activity Index. <i>Arthritis Care and Research</i> , 2014, 66, 1775-1782.	1.5	71
64	Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2014, 41, 2078-2084.	1.0	16
65	Risk of malignancy associated with biologic agents in pediatric rheumatic disease. <i>Current Opinion in Rheumatology</i> , 2014, 26, 538-542.	2.0	15
66	Imaging of the Temporomandibular Joint in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 47-54.	1.5	59
67	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1942-1948.	0.5	100
68	Treatment advances in systemic juvenile idiopathic arthritis. <i>F1000prime Reports</i> , 2014, 6, 21.	5.9	32
69	Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report. <i>Pediatric Rheumatology</i> , 2013, 11, 25.	0.9	27
70	Association Between the Initiation of Anti-Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 887.	3.8	187
71	What is the Background Incidence of Malignancy in Children with Rheumatic Disease?. <i>Current Rheumatology Reports</i> , 2013, 15, 310.	2.1	22
72	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. <i>Arthritis and Rheumatism</i> , 2013, 65, 2499-2512.	6.7	211

#	ARTICLE	IF	CITATIONS
73	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. <i>Arthritis Care and Research</i> , 2013, 65, 1551-1563.	1.5	211
74	Tumor necrosis factor \pm inhibitor therapy and cancer risk in chronic immune-mediated diseases. <i>Arthritis and Rheumatism</i> , 2013, 65, 48-58.	6.7	110
75	Infectious Complications in Juvenile Idiopathic Arthritis. <i>Current Rheumatology Reports</i> , 2013, 15, 327.	2.1	25
76	Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis: From the Safety Assessment of Biologic ThERapy (SABER) Study. <i>American Journal of Ophthalmology</i> , 2013, 155, 183-189.e1.	1.7	60
77	Brief Report: Incidence of Selected Opportunistic Infections Among Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1384-1389.	6.7	53
78	Race, Ethnicity, and Disease Outcomes in Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. <i>Journal of Rheumatology</i> , 2013, 40, 936-942.	1.0	40
79	High Doses of Infliximab in the Management of Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1749-1755.	1.0	56
80	Using Registries to Identify Adverse Events in Rheumatic Diseases. <i>Pediatrics</i> , 2013, 132, e1384-e1394.	1.0	25
81	Enthesitis-related Arthritis Is Associated with Higher Pain Intensity and Poorer Health Status in Comparison with Other Categories of Juvenile Idiopathic Arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Journal of Rheumatology</i> , 2012, 39, 2341-2351.	1.0	80
82	Risk Factors for Temporomandibular Joint Arthritis in Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 1880-1887.	1.0	106
83	Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. <i>Contemporary Clinical Trials</i> , 2012, 33, 1211-1216.	0.8	23
84	Disease-modifying Antirheumatic Drug Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry. <i>Journal of Rheumatology</i> , 2012, 39, 1867-1874.	1.0	76
85	Intra-Articular Corticosteroid Injections to the Temporomandibular Joints Are Safe and Appear to Be Effective Therapy in Children With Juvenile Idiopathic Arthritis. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012, 70, 1802-1807.	0.5	77
86	Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012, 64, 1480-1489.	1.5	49
87	Back mobility and interincisor distance ranges in racially diverse North American healthy children and relationship to generalized hypermobility. <i>Pediatric Rheumatology</i> , 2012, 10, 17.	0.9	8
88	Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1001-1010.	1.5	172
89	Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. <i>Arthritis and Rheumatism</i> , 2012, 64, 1263-1271.	6.7	150
90	Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. <i>Arthritis and Rheumatism</i> , 2012, 64, 2773-2780.	6.7	148

#	ARTICLE	IF	CITATIONS
91	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	1.5	1,413
92	Geographic Distribution of Endemic Fungal Infections among Older Persons, United States. <i>Emerging Infectious Diseases</i> , 2011, 17, 1664-1669.	2.0	158
93	High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. <i>Pediatric Rheumatology</i> , 2011, 9, 20.	0.9	13
94	Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1199-1209.	0.9	29
95	Measuring process of arthritis care: A proposed set of quality measures for the process of care in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 10-16.	1.5	53
96	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care and Research</i> , 2011, 63, 465-482.	1.5	658
97	Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 180-181.	1.0	78
98	Initiation of Tumor Necrosis Factor- α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2331-9.	3.8	305
99	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1401-1406.	0.5	98
100	Temporomandibular Joint Arthritis in Pediatric Sjögren Disease and Sarcoidosis. <i>Journal of Rheumatology</i> , 2011, 38, 2272-2273.	1.0	10
101	Attainment of Inactive Disease Status Following Initiation of TNF- α Inhibitor Therapy for Juvenile Idiopathic Arthritis: Enthesitis-related Arthritis Predicts Persistent Active Disease. <i>Journal of Rheumatology</i> , 2011, 38, 2675-2681.	1.0	48
102	Type 1 Hyperlipoproteinemia and Recurrent Acute Pancreatitis due to Lipoprotein Lipase Antibody in a Young Girl with Sjögren's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3302-3307.	1.8	23
103	Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. <i>Osteoporosis International</i> , 2010, 21, 1573-1584.	1.3	18
104	Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2499-2509.	6.7	19
105	Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?. <i>Pediatric Rheumatology</i> , 2010, 8, 23.	0.9	29
106	Rituximab Therapy for Severe Refractory Chronic Henoch-Schönlein Purpura. <i>Journal of Pediatrics</i> , 2009, 155, 136-139.	0.9	64
107	Optimal treatment of knee monoarthritis in juvenile idiopathic arthritis: A decision analysis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1580-1588.	6.7	27
108	Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). <i>Journal of Rheumatology</i> , 2008, 35, 343-8.	1.0	114

#	ARTICLE	IF	CITATIONS
109	Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. <i>Pediatric Radiology</i> , 2007, 37, 544-548.	1.1	37
110	Juvenile idiopathic arthritis classification criteria: loopholes and diagnosis software. <i>Journal of Rheumatology</i> , 2007, 34, 234; author reply 234-5.	1.0	8
111	Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1133-8.	1.0	245
112	Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. <i>Journal of Rheumatology</i> , 2007, 34, 1918-24.	1.0	18
113	Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 2330-6.	1.0	25
114	Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>ACR Open Rheumatology</i> , 0, , .	0.9	1